Sam Fazeli

@adamfeuerstein Au revoir les blues

What do we have here?!?!? 🇪🇸🇪🇸

@adamfeuerstein A lot can happen in 25 min

Bye Morocco. ☹️

@drrjparkes @adamfeuerstein lol

@SamFazeli8 @adamfeuerstein Watched on replay at 7am. Amazing game but shortened my life.

Holy shit, what a game.

$MRNA share price move, $GMAB $ABBV Epkinly win Pharma In 2H; PD-1 Biosimilars; Merck Suit $MRK $HALO $BMY $RHHBY $AZN $LLY $NVO: BI Drug Call by Bloomberg Intelligence on #SoundCloud on.soundcloud.com/VtKdYPNQ8UenD6…

@adamfeuerstein I was getting very depressed

My man, Harry Kane.

@AAMortazavi @JMaraganore @scidem @jrkelly Oh - and of course they did develop Carvykti and Brukinsa - but ‘brute force’ is the vast majority of the advantage.

True. China do “no innovation” is an exaggeration. But the main business model is me too targets, fast/cheap pre clinical development (missing out animal disease models etc because someone else has done this) and then their big advantage - much faster and less regulation in early human trials. The latter being perhaps the biggest edge imo.

Thanks for asking @jrkelly. It highlights why you and your hawks are not quite getting it here. This is about finding the best innovation for patients from anywhere in the world. I fully expect the cost of developing these assets in the U.S. will be largely the same. For e.g., the Akeso/Summit anti-PD1/VEGF bispecific was discovered in China. Summit was excited about the data and in-licensed it for ex-China rights. Summit is doing robust global clinical studies to demonstrate safety and efficacy. If successful, American patients will get access to a best-in-class immunotherapy that could be a game changer. To my knowledge, there wasn’t an alternative PD1-VEGF bispecific discovered in the U.S. Also, there was no stealing of IP by Akeso to make their drug. Why is this different than Merck sourcing Keytruda from Belgium? So, let’s not use walls to block access to innovation from ANYWHERE in the world especially when it can help US patients. Of course, IP MUST be respected, or the “discovery” is a violation of international law. To clarify one other point, I also want the U.S. to be the indisputable global leader in biotechnology! China’s increased prominence must be a SPUTNIK moment for our country. We should reverse the self-inflicted damage to our innovation ecosystem that includes decimated NIH funding, an anti-science/anti-vaccine/anti-“expert” rhetoric that threatens discourse, a restricted H-1B visa program blocking our ability to recruit the best in the world, a chaotic FDA where innovators and drug developers face enormous uncertainty and undue regulatory hurdles and costs, an effort to break our innovation reward system with drug price controls through Biden-era IRA and Trump-era MFN, a post-COVID hybrid workforce approach that has American’s working less, and more. I, for one, believe that we can WIN with good ole American ingenuity if we course correct on the above. I’m certain that will work. We have the greatest scientists in the world and lead in disruptive innovation while others are making progress in incremental innovation. For those of you that advocate for walls, I don’t think it will be successful. AND, I’m certain American patients will suffer. My $0.02.

While I generally agree that the quantity of innovation is still magnitudes lower, is PD-1xVEGF not an innovation? I know they are known MOAs, but there seems to be synergy there - though solid proof vs Keytruda is still outstanding. Is PD-1xIL2 not an innovation? Again, known MOAs, but China did it and the West did not.

People are missing an important point. The me too biotech VC algorithm post the 2021 crash is obviously going to look for the cheapest and fastest way to and through the clinic - China. But China isn’t innovating, it’s just copying and fast followers. Biotech globally has an innovation funding problem - there’s almost no capital for it. The companies conform to the formula set by the capital - and it’s a vicious circle. I don’t think a new Alnylam/Moderna would get funded today.

@bradloncar Do you think it would have gathered more interest now - all I hear is cynicism

When I launched my China biotech fund on Nasdaq eight years ago, literally nobody wanted to hear about it. Now China is all anybody talks about here.

@adamfeuerstein Just doesn’t give up

@adamfeuerstein Unbelievable!!!

Messi magic.

@adamfeuerstein @Jasonmmast So we basically lost about a year with Makary and Prasad?

FDA reverses course on Regenxbio’s $RGNX childhood gene therapy after rejection statnews.com/2026/06/22/fda… via @Jasonmmast

Mag7+intel+micron+dell+spaceX $SPCX revenue is expected to grow from $2.3 trillion in 2025 to $5.6 trillion in 2030. That means in 2030 they will take 4% of the global GDP (assuming annual growth of 3% of the global economy at $125 trillion in 2026). This compares with c.2% in 2026. So who is losing out? Or may be these estimates are wrong?

$XBI at a 5 years high - hurrah 🎉

This was a first for the Vanguards podcast with Bristol Myers $BMY. You see it’s just over 1 hour and we had to cut short. What a great conversation. Have a listen and ask me any questions. Cheers podcasts.apple.com/gb/podcast/van…

@adamfeuerstein So this was entirely an issue with FDA management?

$QURE uniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease uniqure.com/investors-medi…

@adamfeuerstein Wow

CAPE VERDE!!!

@PCM_bio @BiotechCH @soowannaway @EricSchmidt151 @MatteisPaul @FT @mroliverbarnes @gline @daphnezohar @JMaraganore @LifeSciVC @bradloncar @TimOpler @t_lorriman Agree - but you would need to also calculate the cost getting the drugs to where they are now since the acquisition. Still, I would think it has a positive return.

@BiotechCH @soowannaway @EricSchmidt151 @MatteisPaul @FT @mroliverbarnes @SamFazeli8 @gline @daphnezohar @JMaraganore @LifeSciVC @bradloncar @TimOpler @t_lorriman Common misconception @EricSchmidt151 .. $gsk $tsro acquisition has been quite successful even though Zejula topping out in $700mm range. Jemperli did over $1.1bn last year. Not too shabby for $5.1bn TV…

On today’s #BiotechHangout, @soowannaway (Graig Suvannavejh), @EricSchmidt151, @MatteisPaul & @FT’s @mroliverbarnes will cover the markets: Parabilis’ ($PBLS) record $670M IPO, Kardigan ($KARD) expected to price, SonoThera $125M Series B, City $100M Series B, Ethyreal $101M Series A, big secondary raises, $SMMT’s $500M follow-on pulled, deals: $INCY/Vega ($2B), $GSK/$NUVL ($10.6B), Roche/$NRIX ($3B), $JNJ/Firefly ($1B), $LLY/AlzeCure, $NVS/Orionis, data: $TNGX/$RVMD in 2L+ pancreatic cancer & readthroughs to $IDYA, $SNY CIDP miss hits $DNTH stock, $TAK’s oral TYK2 beats $BMY in Ph3 head-to-head, Sensorion drops hearing loss gene therapy, #EHA2026, $NGNE dosing safety update, plus Blood Cancer United buys remaining supply of Luvelta, & much more: x.com/i/spaces/1qjdz…

@adamfeuerstein So not M&A?

$SMMT pulled its proposed $500M offering "due to market conditions" sec.gov/ix?doc=/Archiv…

Wish I could spell :-) on a roll!!

Leerink is on a role and it’s a great positive sign for the sector too: a big M&A $NUVL and a very successful IPO $PBLS - congrats.